t
GSK plc (the 'Company')
Transaction notification
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Mr L Miels |
|||
|
b) |
Position/status |
Chief Commercial Officer |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Following the vesting on 4 September 2023 of 25% of an award made on 14 February 2018 under the GlaxoSmithKline Deferred Investment Award Programme, Mr Miels will receive a cash payment of £419,289.21 less applicable tax withholding in respect of 30,524.840 notional Ordinary Shares. |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£13.7360 |
30,524.840 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2023-09-04 |
|||
|
f) |
Place of the transaction
|
N/A |
|||
| Date | 6 Sept 2023 |
| Time | 15:30:01 |
| Category | Director/PDMR dealings |
| ID | 6018L |